Clinical trials: Liver Fat
Non-Alcoholic Fatty Liver Disease, Obesity
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat
- Trial name
- NCT03375788
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Morbid Obesity, Liver Fat
Low-calorie Diet and Body Composition Prior to Roux-en-Y Gastric Bypass
Losing weight before undergoing Roux-en-Y gastric bypass (RYGB) surgery may reduce liver fat content and size thereby improving surgical outcomes.
- Trial name
- LCD (NCT02144597)
- Testing
- Liquid formula low-calorie diet (LCD), Roux-en-Y gastric bypass (RYGB), Control diet
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Imperial College London